Production of neutralizing granulocyte-macrophage colony-stimulating factor (GM-CSF) antibodies in carcinoma patients following GM-CSF combination therapy

Clinical and Experimental Immunology

Volumn 104, Issue 2, 1996, Pages 351-358

  Wadhwa, M ^a   Bird, C ^a   Fagerberg, J ^b   Gaines Das, R ^a   Ragnhammar, P ^b   Mellstedt, H ^b   Thorpe, R ^a  

^a NATIONAL INSTITUTE FOR BIOLOGICAL STANDARDS AND CONTROL   (United Kingdom)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Antibody production; Clinical effects; Cross reactivity; GM CSF; Neutralization

Indexed keywords

CYTOKINE ANTIBODY; MONOCLONAL ANTIBODY; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR;

ADOLESCENT; ADULT; AGED; ANTIBODY PRODUCTION; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CARCINOMA; CROSS REACTION; HUMAN; PRIORITY JOURNAL;

EID: 0029920487     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2249.1996.11704.x     Document Type: Article

References (31)

1. Steis RG, Smith JW, Urba WJ et al. Resistance to recombinant interferon alfa-2a in hairy-cell leukaemia associated with neutralizing anti-interferon antibodies. N Engl J Med 1988; 318:1409-13.
2. Freund M, von Wussow P, Diedrich H et al. Recombinant human interferon (IFN) alpha-2b in chronic myelogenous leukaemia: dose dependency of response and frequency of neutralizing anti-interferon antibodies. Br J Haematol 1989; 72:350-6.
3. Lok ASF, Lai CL. Incidence, neutralizing activity and clinical significance of interferon antibodies in chronic hepatitis B patients receiving recombinant α-interferons. In: Hollinger, Lennon and Margolis, eds. Viral hepatitis and liver disease. Baltimore: Williams & Wilkes, 1991:643-5.
4. Antonelli G, Currenti M, Turriziani O, Dianzani F. Neutralizing antibodies to interferon-α: relative frequency in patients treated with different interferon preparations. J Infect Dis 1991; 163:882-5.
5. Galton JE, Bedford P, Scott JE. Antibodies to lymphoblastoid interferon. Lancet 1989; ii:572-3.
6. Milella M, Antonelli G, Santantonio T, Others A. Neutralizing antibodies to recombinant alpha interferon and response to therapy in chronic hepatitis C virus infection. Liver 1993; 13:146-50.
7. Rönnblom LE, Tiensuujanson E, Perers A. Characterization of anti-interferon-α antibodies appearing during recombinant interferon-α2a treatment. Clin Exp Immunol 1992; 89:330-5.
8. Sieff CA, Emerson SG, Donahue RE, Nathan DG, Wang EA, Wong GG, Clark SC. Human recombinant granulocyte-macrophage colony-stimulating factor: a multilineage hematopoietin. Science 1985; 230:1171-3.
9. Vadas M, Nicola N, Metcalf D. Activation of antibody dependent cell mediated cytotoxicity of human neutrophils and eosinophils by separate colony stimulating factors. J Immunol 1983; 130:795-9.
10. Masucci P, Wersäll P, Ragnhammar P, Mellstedt H. Granulocyte-monocyte-colony-stimulating factor augments the cytotoxic capacity of lymphocytes and monocytes in antibody-dependent cellular cytotoxicity. Cancer Immunol Immunother 1989; 29:288-92.
11. Gamble JR, Elliott MJ, Jaipargas E, Lopez AF, Vadas MA. Regulation of human monocyte adherence by granulocyte-macrophage colony-stimulating factor. Proc Natl Acad Sci USA 1989; 86:7169-73.
12. Arnaout M, Wang E, Clark S, Sieff C. Human recombinant granulocyte-macrophage colony-stimulating factor increases cell to cell adhesion and surface expression of adhesion promoting glycoproteins on mature granulocytes. J Clin Invest 1986; 78:597-601.
13. Morrissey P, Bressler L, Park L, Alpert A, Gillis S. Granulocyte-macrophage colony-stimulating factor augments the primary antibody response by enhancing the function of antigen presenting cells. J Immunol 1987; 139:1113-9.
14. Grabstein K, Urdal D, Tushinski R. Induction of tumoricidal activity by granulocyte-macrophage colony-stimulating factor. Science 1986; 232:506-8.
15. Dranoff G, Jaffee E, Lazenby A et al. Vaccination with irradiated tumor cells engineered to secret murine granulocyte macrophage colony-stimulating factor stimulates potent, specific and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA 1993; 90:3539-43.
16. Costello RT. Therapeutic use of granulocyte-macrophage colony-stimulating factor (GM-CSF). Acta Oncol 1993; 32:403-8.
17. Ragnhammar P, Fagerberg J, Frödin J-E et al. Effect of monoclonal antibody 17-1A and GM-CSF in patients with advanced colorectal carcinoma-long-lasting, complete remissions can be induced. Int J Cancer 1993; 53:751-8.
18. Dorr RT. Clinical properties of yeast-derived versus Escherichia coli-derived granulocyte-macrophage colony-stimulating factor. Clinical Therapeutics 1993; 15:19-29.
19. Wong GC, Witeck JS, Temple PA. Human GM-CSF: molecular cloning of the complementary DNA and purification of the natural and recombinant proteins. Science 1985; 228:810-5.
20. Burgess AW, Begley CG, Johnson GR et al. Purification and properties of bacterially synthesized human granulocyte-macrophage colony stimulating factor. Blood 1987; 69:43-51.
21. Cantrell MA, Anderson D, Cerretti DP. Cloning, sequence and expression of a human granulocyte macrophage colony stimulating factor. Proc Natl Acad Sci USA 1985; 82:6250-4.
22. Gribben JG, Devereux S, Thomas NSB, Keim M, Jones HM, Goldstone AH, Linch DC. Development of antibodies to unprotected glycosylation sites on recombinant human GM-CSF. Lancet 1990; 335:434-7.
23. Thompson JA, Lee DJ, Kidd P, Rubin E, Kaufman J, Bonnem EM, Fefer A. Subcutaneous granulocyte macrophage colony-stimulating factor in patients with myelodysplastic syndrome: toxicity pharmacokinetics and hematological effects. J Clin Oncol 1989; 7:629-37.
24. Greenberg PL, Negrin R, Nagler A. The use of haemopoietic growth factors in the treatment of myelodysplastic syndromes. Cancer Surv 1990; 9:199-212.
25. Ragnhammar P, Friesen H-J, Frödin J-E, Lefvert A-K, Hassan M, Österborg A, Mellstedt H. Induction of anti-recombinant human granulocyte-macrophage colony-stimulating factor (Escherichia coli-derived) antibodies and clinical effects in nonimmunocompromised patients. Blood 1994; 84: 4078-87.
26. Kitamura T, Tange T, Terasawa T et al. Establishment and characterisation of a unique human cell line that proliferates dependently on GM-CSF, IL-3, or erythropoietin. J Cell Physiol 1989; 140:323-34.
27. Wadhwa M, Bird C, Page LA, Mire-Sluis AR, Thorpe R. Quantitative biological assays for individual cytokines. In: Balkwill FR, ed. Cytokines - a practical approach, 2nd edn. Oxford: IRL Press, 1995:357-91.
28. Kirkwood TBL. Geometric means and measures of dispersion. Biometrics 1979; 35:908-9.
29. Bird C, Wadhwa M, Thorpe R. Development of immunoassays for human IL-3 and IL-4 some of which discriminate between different recombinant DNA derived molecules. Cytokine 1991; 3: 562-7.
30. von Wussow P, Freund M, Block B, Diedrich H, Poliwoda H, Deicher H. Clinical significance of anti-IFN-alpha antibody titers during Interferon therapy. Lancet 1987; 2:635-6.
31. von Wussow P, Pralle H, Hochkeppel H-K et al. Effective natural interferon-α therapy in recombinant interferon-α-resistant patients with hairy cell leukaemia. Blood 1991; 78:38-43.